UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $93.24 Million Stock Position in Bio-Rad Laboratories, Inc. $BIO

Key Points

• UBS Asset Management reduced its holdings in Bio-Rad Laboratories by 1.5%, retaining 382,807 shares worth approximately $93.2 million.
• Other large investors, including Dimensional Fund Advisors and Ariel Investments, increased their positions significantly, with Dimensional growing its holdings by 17.5%.
• Analysts have mixed ratings on Bio-Rad, with a consensus rating of "Moderate Buy" and an average target price of $333.50, while several upgraded and downgraded their price targets recently.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC reduced its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 382,807 shares of the medical research company's stock after selling 5,820 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 1.37% of Bio-Rad Laboratories worth $93,236,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Principal Financial Group Inc. boosted its stake in Bio-Rad Laboratories by 0.5% in the first quarter. Principal Financial Group Inc. now owns 44,343 shares of the medical research company's stock valued at $10,800,000 after buying an additional 236 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in Bio-Rad Laboratories by 14.6% in the first quarter. Crossmark Global Holdings Inc. now owns 966 shares of the medical research company's stock valued at $235,000 after buying an additional 123 shares in the last quarter. Amundi boosted its stake in Bio-Rad Laboratories by 16.4% in the first quarter. Amundi now owns 23,336 shares of the medical research company's stock valued at $5,478,000 after buying an additional 3,294 shares in the last quarter. New York State Teachers Retirement System boosted its stake in Bio-Rad Laboratories by 1.2% in the first quarter. New York State Teachers Retirement System now owns 17,500 shares of the medical research company's stock valued at $4,262,000 after buying an additional 200 shares in the last quarter. Finally, Asset Management One Co. Ltd. boosted its stake in Bio-Rad Laboratories by 4.6% in the first quarter. Asset Management One Co. Ltd. now owns 7,182 shares of the medical research company's stock valued at $1,749,000 after buying an additional 315 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on BIO. Zacks Research raised Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 26th. Royal Bank Of Canada increased their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, August 22nd. Finally, Wells Fargo & Company increased their target price on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $333.50.

Bio-Rad Laboratories Trading Up 2.0%

Shares of BIO traded up $5.69 during mid-day trading on Thursday, reaching $285.98. 176,442 shares of the company were exchanged, compared to its average volume of 230,275. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $387.99. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12. The stock has a market capitalization of $7.74 billion, a PE ratio of 24.38 and a beta of 0.95. The business has a 50 day simple moving average of $274.67 and a two-hundred day simple moving average of $252.53.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The company had revenue of $651.60 million during the quarter, compared to the consensus estimate of $614.82 million. During the same period last year, the company earned $3.11 earnings per share. The firm's revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.